RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
1-Year Return
25.98%
This Quarter Return
-1.44%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.75B
AUM Growth
-$879M
(-33%)
Cap. Flow
-$729M
Cap. Flow
% of AUM
-41.7%
Top 10 Holdings %
Top 10 Hldgs %
36.57%
Holding
113
New
6
Increased
25
Reduced
47
Closed
16
Top Buys
| 1 |
Tarsus Pharmaceuticals
TARS
|
$12.5M |
| 2 |
Danaher
DHR
|
$12.1M |
| 3 |
Evolent Health
EVH
|
$6.02M |
| 4 |
Mineralys Therapeutics
MLYS
|
$5.09M |
| 5 |
Merus
MRUS
|
$3.71M |
Top Sells
| 1 |
Intuitive Surgical
ISRG
|
$56.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
$48.8M |
| 3 |
Freshpet
FRPT
|
$48.5M |
| 4 |
UnitedHealth
UNH
|
$39.5M |
| 5 |
Travere Therapeutics
TVTX
|
$36.8M |
Sector Composition
| 1 | Healthcare | 99.7% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Agios Pharmaceuticals
AGIO
$2.09B
| $10M | 0.57% |
342,180
-128,906
| -27% | -$3.78M |
|
52
Pharvaris
PHVS
$1.48B
| $9.79M | 0.56% |
623,402
-151,729
| -20% | -$2.38M |
|
53
Compass Therapeutics
CMPX
$590M
| $9.43M | 0.54% |
4,962,955
-816,620
| -14% | -$1.55M |
|
54
Enliven Therapeutics
ELVN
$1.19B
| $9.17M | 0.52% |
465,871
+37,300
| +9% | +$734K |
|
55
Soleno Therapeutics
SLNO
$3.71B
| $8.87M | 0.51% |
124,095
| – | – |
|
56
Ardelyx
ARDX
$1.57B
| $7.88M | 0.45% |
1,604,975
+141,346
| +10% | +$694K |
|
57
Aclaris Therapeutics
ACRS
$227M
| $7.72M | 0.44% |
5,046,309
-1,158,000
| -19% | -$1.77M |
|
|
ZBIO
58
Zenas BioPharma, Inc. Common Stock
ZBIO
$864M
| $6.94M | 0.4% |
878,667
| – | – |
|
59
89bio
ETNB
$1.32B
| $6.14M | 0.35% |
844,441
+291,700
| +53% | +$2.12M |
|
60
Prothena Corp
PRTA
$460M
| $6.1M | 0.35% |
492,601
-152,000
| -24% | -$1.88M |
|
61
Janux Therapeutics
JANX
$1.44B
| $5.52M | 0.32% |
204,466
| – | – |
|
62
Dyne Therapeutics
DYN
$2.02B
| $5.49M | 0.31% |
524,499
+49,971
| +11% | +$523K |
|
|
63
Mineralys Therapeutics
MLYS
$2.7B
| $5.09M | 0.29% |
+320,813
| New | +$5.09M |
|
64
Cullinan Oncology
CGEM
$413M
| $4.88M | 0.28% |
644,633
-97,481
| -13% | -$738K |
|
|
NVRO
65
DELISTED
NEVRO CORP.
NVRO
| $4.67M | 0.27% |
800,494
-847,606
| -51% | -$4.95M |
|
|
BCAX
66
Bicara Therapeutics Inc. Common Stock
BCAX
$658M
| $4.38M | 0.25% |
336,070
-109,905
| -25% | -$1.43M |
|
67
Novavax
NVAX
$1.28B
| $4.17M | 0.24% |
650,000
| – | – |
|
|
KMTS
68
Kestra Medical Technologies, Ltd. Common Stock
KMTS
$873M
| $3.61M | 0.21% |
+145,000
| New | +$3.61M |
|
69
Gossamer Bio
GOSS
$668M
| $3.59M | 0.21% |
3,266,960
| – | – |
|
70
Pulmonx
LUNG
$70.9M
| $3.39M | 0.19% |
503,700
-268,451
| -35% | -$1.81M |
|
|
INZY
71
DELISTED
Inozyme Pharma
INZY
| $3.14M | 0.18% |
3,445,299
-416,684
| -11% | -$379K |
|
72
Beam Therapeutics
BEAM
$2.11B
| $2.93M | 0.17% |
150,020
-102,203
| -41% | -$2M |
|
73
Alphatec Holdings
ATEC
$2.43B
| $2.71M | 0.16% |
267,500
+67,500
| +34% | +$684K |
|
74
Sagimet Biosciences
SGMT
$231M
| $2.57M | 0.15% |
787,808
| – | – |
|
|
EDAP
75
EDAP TMS
EDAP
$94.2M
| $2.49M | 0.14% |
1,270,000
-321,800
| -20% | -$631K |
|